More CEO watchers put Gilead's Martin on their 'best of 2014' lists

End-of-year bouquets are piling up for Gilead Sciences ($GILD) CEO John Martin. After winning top reviews from the Harvard Business Review for his 2014 performance, Martin has picked up a "best CEO" nod from a prof at Dartmouth's Tuck School of Business. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs. Report

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.